Maya Guglin (@mguglin) 's Twitter Profile
Maya Guglin

@mguglin

Section Chief, Heart Failure/Transplant at Rutgers University. Professor of Medicine

ID: 1043337994026065921

calendar_today22-09-2018 03:15:36

359 Tweet

479 Followers

76 Following

Adrian da Silva (@adrianjdasilva) 's Twitter Profile Photo

New in JACC Heart Failure: Metolazone + IV Furosemide led to higher natriuresis; urine volume; and weight loss than IV furosemide alone or in combination with Acetazolamide in ambulatory #HF patients shorturl.at/GnMiB

New in JACC Heart Failure: 

Metolazone + IV Furosemide led to higher natriuresis; urine volume; and weight loss than IV furosemide alone or in combination with Acetazolamide in ambulatory #HF patients

shorturl.at/GnMiB
Anthony Carnicelli, MD FACC (@carnicelli_ant) 's Twitter Profile Photo

🔥 Now in Circ: HF🔥 Acute hemodynamic effect of pacing in HM3 patients (HURRY-LVAD) - prospective, invasive hemo study of HM3 pts w ppm - main findings: ⬆️ pacing rate ➡️ worsening RV hemos, ⬆️ PAWP, and no change in CO/CI ahajournals.org/doi/10.1161/CI…

Rushin Patel MD (@rushin311) 's Twitter Profile Photo

#Obesity 🔄 #HFpEF SGLT2i & GLP1RA independently benefit HFpEF. However, incremental benefits of both underexplored JACC Journals study: #GLP1RA ➡️ incremental benefits in addition to #SGLT2i for pts with HFpEF, Obesity & T2DM

#Obesity 🔄 #HFpEF 
SGLT2i &amp; GLP1RA independently benefit HFpEF. However, incremental benefits of both underexplored <a href="/JACCJournals/">JACC Journals</a> study: #GLP1RA ➡️ incremental benefits in addition to #SGLT2i for pts with HFpEF, Obesity &amp; T2DM
Novi Tham (@slumberbell) 's Twitter Profile Photo

Exciting Results from #HELIOS_B Trial! 🌟 📍Double-blind, randomized 📍#Vutrisiran in #hereditary or wt #ATTR_CM 📍655 px, mostly elderly males with NYHA FCII 📍#Vutrisiran 25 mg vs. placebo q3 mo, plus #tafamidis if ongoing 🎯 Results: 📍Primary Endpoint: Significant ⬇️ in

Exciting Results from #HELIOS_B Trial! 🌟

📍Double-blind, randomized
📍#Vutrisiran in #hereditary or wt #ATTR_CM
📍655 px, mostly elderly males with NYHA FCII
📍#Vutrisiran 25 mg vs. placebo q3 mo, plus #tafamidis if ongoing

🎯 Results:
📍Primary Endpoint: Significant ⬇️ in
Adrian da Silva (@adrianjdasilva) 's Twitter Profile Photo

In the #DOAC #LVAD (phase II trial): #Apixaban + ASA 81 mg (vs Warfarin + ASA 81 mg) was NOT associated with excess mortality or major hemocompatibility events in patients with HeartMate 3 For more details: shorturl.at/hD7AG

In the #DOAC #LVAD (phase II trial): #Apixaban + ASA 81 mg (vs Warfarin + ASA 81 mg) was NOT associated with excess mortality or major hemocompatibility events in patients with HeartMate 3

For more details: shorturl.at/hD7AG
Novi Tham (@slumberbell) 's Twitter Profile Photo

🔥All you need to know about #AFib & #HFrEF, a 🧵: 1/n 📍Staging: 1️⃣: At-risk (#obesity, #HTN, #Diabetes) 2️⃣: Pre-AF (structural/functional atrial changes w/o clinical #AF). 3️⃣: #AF (paroxysmal, persistent, longstanding-persistent, successful ablation) 4️⃣: Permanent 🖇️:

🔥All you need to know about #AFib &amp; #HFrEF, a 🧵:

1/n
📍Staging:
1️⃣: At-risk (#obesity, #HTN, #Diabetes)
2️⃣: Pre-AF (structural/functional atrial changes w/o clinical #AF).
3️⃣: #AF (paroxysmal, persistent, longstanding-persistent, successful ablation)
4️⃣: Permanent

🖇️: